Cannabis Science Inc. Announces Advances In Its Analytical Lab Logistics
COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science Inc. (NASD OTCBB: CBIS), a pharmaceutical cannabis company in the US, is pleased to announce progress in its Analytical Lab Division at Cannabis Science. Cannabis Science Inc., President & CEO, Dr. Robert Melamede Ph.D., explained, " As a patient oriented company located in a state with effective medical marijuana laws, we are able to study the medical production and use of cannabis in a variety of modalities. At the core of this research, we are working with patients producing top grade medical cannabis as the starting point for extracts and formulations to treat the many disease states that cannabinoids positively impact. Efficient, stable propagation and quality control of the starting material and downstream processes are essential to this progress."
There are several integral and interdependent facets of this approach:
Lab Division:
I. Propagation
a. Traditional Cloning, Micropropagation & Extensive Seed Bank
II. QC & Analytics
a. Genetic QC such as Fingerprinting
b. Biochemical & Contaminant QC including HPLC and GC
III. Extracts and Formulations
IV. Final Product Testing
a. Local clinical Trials
b. FDA Clinical Trials
Dr. Robert Melamede concluded, “The Colorado Medical Marijuana Community provides a diverse population to conduct preliminary trials of our products. As patients, we have direct and open communication with the community. With our new discussion forum and this local involvement, we have a resource in our community for testing our products. Our platform introduces innovative combinations for medical cannabis use. Each uses a specific formulation and delivery method that will be used downstream in final testing in human clinical trials. Once our cannabis strains are selected for specific ailments, those formulations can be applied to oral, digestive, transdermal, and pulmonary delivery routes to combat specific age-related illnesses or other disease states we are interested in targeting, such as PTSD, chronic pain, and influenza. At Cannabis Science we believe we will provide a new era of reliable, safe and effective cannabis medicines.”
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.